Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198328 · ClinicalTrials.gov registry record · Phase 3
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
A Phase 3 study, sponsored by Inovio Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT00198328 is a Phase 3 study that was terminated before completion, run by Inovio Pharmaceuticals. The registered enrollment target is 84 participants.
The verdict
NCT00198328, a Phase 3 study, was terminated before completion, sponsored by Inovio Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx or larynx.
Interventions
- COMBINATION_PRODUCT Medpulser Electroporation with Bleomycin
- PROCEDURE Surgical Excision
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198328
The ClinicalTrials.gov registry entry for NCT00198328 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medpulser Electroporation with Bleomycin is the first listed.
NCT00198328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198328 about?
NCT00198328 is a clinical study titled "Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma". The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the base of the tongue, posterior lateral ...
What is the current status of trial NCT00198328?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2004-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00198328?
The interventions under investigation include: Medpulser Electroporation with Bleomycin (COMBINATION_PRODUCT), Surgical Excision (PROCEDURE).
Who is sponsoring clinical trial NCT00198328?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.